期刊文献+

Challenges and Possibilities of Cell-Based Tissue-Engineered Vascular Grafts 被引量:1

原文传递
导出
摘要 There is urgent demand for biologically compatible vascular grafts for both adult and pediatric patients.The utility of conventional nonbiodegradable materials is limited because of their thrombogenicity and inability to grow,while autologous vascular grafts involve considerable disadvantages,including the invasive procedures required to obtain these healthy vessels from patients and insufficient availability in patients with systemic atherosclerosis.All of these issues could be overcome by tissue-engineered vascular grafts(TEVGs).A large body of evidence has recently emerged in support of TEVG technologies,introducing diverse cell sources(e.g.,somatic cells and stem cells)and novel fabrication methods(e.g.,scaffold-guided and self-assembled approaches).Before TEVG can be applied in a clinical setting,however,several aspects of the technology must be improved,such as the feasibility of obtaining cells,their biocompatibility and mechanical properties,and the time needed for fabrication,while the safety of supplemented materials,the patency and nonthrombogenicity of TEVGs,their growth potential,and the long-term influence of implanted TEVGs in the body must be assessed.Although recent advances in TEVG fabrication have yielded promising results,more research is needed to achieve the most feasible methods for generating optimal TEVGs.This article reviews multiple aspects of TEVG fabrication,including mechanical requirements,extracellular matrix components,cell sources,and tissue engineering approaches.The potential of periodic hydrostatic pressurization in the production of scaffold-free TEVGs with optimal elasticity and stiffness is also discussed.In the future,the integration of multiple technologies is expected to enable improved TEVG performance.
出处 《Cyborg and Bionic Systems》 2021年第1期16-31,共16页 类生命系统(英文)
基金 supported by the Japan Society for the Promotion of Science(JSPS)KAKENHI(J.S.:JP18K15681,JP16H07107 U.Y.:JP20H03650,JP20K21638,JP18K08767,JP17K19403 M.K.:JP15H05761,JP19H00749,JP20K20987) the Japan Agency for Medical Research and Development(AMED)(Y.I.:19lm0203087h0001,19ek0109240h003) the Miyata Cardiac Research Promotion Foundation(U.Y.).
  • 相关文献

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部